Spironolactone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Spironolactone: From Hypertension and Heart Failure to Androgenetic Alopecia
Note: This evidence pack (TW-DB00421-multi) contains 10 TxGNN-predicted indications for spironolactone, ranging from well-supported dermatological repurposing to unsupported rare-disease artefacts. This report focuses on Alopecia (Androgenetic Alopecia / Female Pattern Hair Loss), the candidate with by far the strongest clinical evidence (L2, Proceed with Guardrails). A summary of the other 9 candidates is provided at the end of this report.
One-Sentence Summary
Spironolactone is a well-established aldosterone (mineralocorticoid) receptor antagonist, classically used as a potassium-sparing diuretic for hypertension, oedema, and heart failure. Among the 10 candidate indications generated by the TxGNN model for this drug, Androgenetic Alopecia shows the strongest supporting evidence, with 2 clinical trials (including 1 completed Phase 2 RCT) and 20 publications, among them a Cochrane systematic review and a JAAD systematic review specifically evaluating spironolactone for this condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the source dataset. Spironolactone is a well-known potassium-sparing diuretic / aldosterone antagonist, classically indicated for hypertension, oedema, primary hyperaldosteronism, and heart failure |
| Predicted New Indication | Alopecia (Androgenetic Alopecia / Female Pattern Hair Loss) |
| TxGNN Prediction Score | 97.83% |
| Evidence Level | L2 |
| EU Market Status | Not marketed (per this dataset’s EMA centrally-authorised product scope; spironolactone is a long-established generic typically authorised via national procedures, which are not captured in this dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed structured mechanism-of-action data for spironolactone is currently marked as a data gap in this record. Based on well-established pharmacology, spironolactone is a synthetic aldosterone receptor antagonist that also exhibits meaningful anti-androgenic activity — it blocks androgen receptors and reduces androgen synthesis. This dual hormonal action is the basis for its long-standing off-label use in dermatology for androgen-driven conditions such as acne, hirsutism, and hair loss.
Androgenetic alopecia (AGA), also known as female pattern hair loss, is directly driven by androgen (dihydrotestosterone) signalling at the hair follicle, causing progressive miniaturisation of terminal hairs into vellus hairs. Because spironolactone antagonises this signalling pathway, it targets the pathology of AGA directly — a mechanistic fit that is notably stronger than several other TxGNN-predicted candidates in this pack (e.g., hypotrichosis simplex, Braddock syndrome), which involve non-androgenic genetic mechanisms with no plausible pharmacological link to spironolactone.
This mechanistic plausibility is reinforced by real-world clinical practice: spironolactone has been used off-label by dermatologists for decades as anti-androgen therapy for female AGA. The repurposing candidate is further supported by a completed Phase 2 RCT directly comparing spironolactone to topical minoxidil, a Cochrane systematic review on interventions for female pattern hair loss, and multiple systematic reviews — including one in the Journal of the American Academy of Dermatology — specifically evaluating its efficacy and safety in this indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00175617 | Phase 2 | Completed | 40 | Direct comparison of oral spironolactone vs. topical minoxidil in female pattern hair loss |
| NCT02483195 | Phase 4 | Withdrawn | 0 | Planned head-to-head comparison of finasteride, spironolactone, and topical minoxidil in postmenopausal female AGA; trial withdrawn before enrollment, no data generated |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37650533 | 2024 | RCT | Journal of Cosmetic Dermatology | Blinded RCT comparing topical minoxidil + oral spironolactone vs. topical minoxidil + oral finasteride in women with AGA |
| 36923692 | 2023 | Systematic Review | Clinical, Cosmetic and Investigational Dermatology | Systematic review of the efficacy and safety of oral and topical spironolactone specifically in AGA treatment |
| 34352345 | 2022 | Systematic Review | Journal of the American Academy of Dermatology | Systematic review of efficacy and safety profile of oral spironolactone for androgenic alopecia |
| 27225981 | 2016 | Cochrane Systematic Review | Cochrane Database of Systematic Reviews | Cochrane review of interventions (including spironolactone) for female pattern hair loss |
| 35038224 | 2022 | Review | Dermatologic Therapy | Overview of spironolactone’s dermatological uses, including its anti-androgenic mechanism relevant to hair loss |
| 37591565 | 2023 | Review | Journal of the American Academy of Dermatology | Review of medical and procedural AGA treatments, discussing spironolactone alongside finasteride and low-dose minoxidil |
| 36039391 | 2022 | Cross-sectional Study | Journal of Cosmetic Dermatology | Dermoscopic evaluation of combined topical spironolactone 5% + minoxidil 5% in AGA treatment |
| 39133327 | 2024 | Retrospective Cohort | Archives of Dermatological Research | Retrospective review of spironolactone + low-dose oral minoxidil combination therapy for alopecia, including tolerability findings |
| 35138351 | 2022 | Systematic Review / Meta-analysis | JAMA Dermatology | Meta-analysis of cancer risk associated with spironolactone use, relevant given its common off-label use in alopecia/acne/hirsutism |
| 38852607 | 2024 | Systematic Review | Journal of Cosmetic and Laser Therapy | Systematic review of oral, topical, and procedural treatment options for androgenic alopecia |
Safety Considerations
Please refer to the SmPC for safety information. Formal warnings, contraindications, and drug-interaction data for spironolactone are not available in this evidence pack (flagged as a Blocking data gap, DG001).
Other Predicted Indications Reviewed
For transparency, the remaining candidates screened in this evidence pack are summarised below. Most show no meaningful clinical or mechanistic support and are not recommended for further evaluation.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 1 | Hypotrichosis simplex of the scalp | 99.26% | L5 | Hold | No supporting trials/literature; non-androgen-driven genetic disorder, no mechanistic fit |
| 2 | Congenital hypotrichosis milia | 99.04% | L5 | Hold | No supporting evidence; rare genetic syndrome with no relevant pathology link |
| 3 | Diffuse alopecia areata | 98.41% | L4 | Research Question | Autoimmune mechanism, not androgen-driven; only indirect literature (AGA review) |
| 5 | Malignant renovascular hypertension | 97.54% | L4 | Research Question | Mechanistically plausible (aldosterone/renin pathway), but literature is diagnostic-methodology only, not treatment evidence |
| 6 | Malignant hypertensive renal disease | 97.54% | L5 | Hold | No supporting literature or trials |
| 7 | Pulmonary hypertension, unclear multifactorial mechanism | 97.33% | L5 | Hold | No supporting literature or trials |
| 8 | Pulmonary hypertension owing to lung disease and/or hypoxia | 97.33% | L5 | Hold | 20 literature hits, all general hypoxia biology, none specific to spironolactone or this indication |
| 9 | Braddock syndrome | 96.64% | L5 | Hold | Ultra-rare genetic syndrome; no supporting evidence |
| 10 | Chronic pulmonary heart disease | 95.55% | L2 | Proceed with Guardrails | Plausible mechanism (aldosterone-mediated cardiac/vascular remodeling); small completed Phase 4 trial (n=15) in chronic right heart failure, plus supportive literature (incl. TOPCAT subanalyses) |
Chronic pulmonary heart disease is the second-best-supported candidate in this pack and may warrant its own dedicated evaluation report given its L2 evidence level.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A completed Phase 2 RCT directly testing spironolactone against topical minoxidil in female pattern hair loss, combined with a Cochrane systematic review and multiple dermatology-society-level systematic reviews, establishes a credible evidence base (L2) and a clear, well-understood mechanistic rationale (androgen receptor antagonism). However, no large confirmatory Phase 3 RCT specific to this drug-indication pairing exists, and formal regulatory safety documentation is currently unavailable.
To proceed, the following is needed:
- TFDA/EMA-labelled warnings, contraindications, and drug-drug interaction data (currently a Blocking data gap, DG001)
- Confirmed DrugBank mechanism-of-action record (High-priority data gap, DG002)
- Verification of actual EU marketing status via national (non-centralised) authorisation registries, since this dataset only captures centrally-authorised EMA products
- A larger, adequately powered confirmatory trial specifically evaluating spironolactone for AGA, given the existing Phase 2 RCT’s small sample size (n=40)
- Route/dosage-form compatibility assessment for the alopecia indication (currently marked pending)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.